Recently, three disease-modifying treatments have been approved for use in SMA patients, including pre-messenger RNA splicing of SMN2 nusinersen (2), SMN2 splicing modifier risdiplam (3), and gene replacement therapy by onasemnogene abeparvovec (4). Here, SMN2 is linked to proximal spinal muscular atrophy.